Eli Lilly recently announced it’s working on certain pharmaceutical pricing changes to comply with President Donald Trump’s "most-favored nation" executive order.

Lilly Looks to Align U.S. Drug Prices with Other Nations Under Trump’s MFN Plan, Cites 340B ‘Abuse’ as Factor in Higher Costs

August 19, 2025 Shannon Young, Associate Editor/Senior Writer Views

An Indiana-based pharmaceutical giant recently announced that it’s working to align its U.S. drug prices with those paid by other [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Lilly Looks to Align U.S. Drug Prices with Other Nations Under Trump’s MFN Plan, Cites 340B ‘Abuse’ as Factor in Higher Costs

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Lilly Looks to Align U.S. Drug Prices with Other Nations Under Trump’s MFN Plan, Cites 340B ‘Abuse’ as Factor in Higher Costs

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Staff Email

Site Footer Live